Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion

被引:0
|
作者
Tomohiro Kawaguchi
Yukihiko Sonoda
Ichiyo Shibahara
Ryuta Saito
Masayuki Kanamori
Toshihiro Kumabe
Teiji Tominaga
机构
[1] Tohoku University Graduate School of Medicine,Department of Neurosurgery
[2] Yamagata University School of Medicine,Department of Neurosurgery, Faculty of Medicine
[3] Kitasato University School of Medicine,Department of Neurosurgery
来源
Journal of Neuro-Oncology | 2016年 / 129卷
关键词
Glioma; WHO grade III; IDH; 1p/19q; Surgery; Magnetic resonance imaging;
D O I
暂无
中图分类号
学科分类号
摘要
The prognosis of patients with WHO grade III gliomas is highly dependent on their genomic status such as the isocitrate dehydrogenase (IDH) 1/2 mutation and1p/19q co-deletion. However, difficulties have been associated with determining which tumors have certain genomic profiles by preoperative radiographical modalities, and the role of surgical resection in achieving better outcomes remains unclear. This retrospective study included 124 consecutive patients with newly diagnosed grade III gliomas. The genomic status of IDH1/2 and 1p/19q was analyzed in these patients. Tumors were then divided into 3 subgroups based on their genomic status; the IDH 1/2 mutation with the 1p/19q co-deletion (1p/19q co-del), the IDH 1/2 mutation without the 1p/19q co-deletion (non-1p/19q co-del), and the IDH 1/2 wild type (IDH wt). Survival times were compared between patients who underwent gross total resection and those who did not (GTR versus non-GTR). The relationships between genomic statuses and MR imaging characteristics such as ring-like or nodular enhancements by gadolinium, and very low intensity on T1-weighted images with blurry enhancements (T1VL) were also examined. Among all patients with grade III gliomas, GTR patients had longer median survival and progression-free times than those of non-GTR patients (undefined versus 87 months, p = 0.097, and 124 versus 34 months, p = 0.059, respectively). No significant differences were observed in survival between GTR and non-GTR patients in the 1p/19q co-del group (p = 0.14), or between GTR and non-GTR patients in the IDH wt group (26 and 27 months, p = 0.29). On the other hand, in non-1p/19q co-del group, survival was significantly longer in GTR patients than in non-GTR patients (undefined versus 77 months, p = 0.005). Radiographically, T1VL was detected in most tumors in the non-1p/19q co-del group (78.2 %), but only 6 (21.4 %) and 17 (41.5 %) tumors in the 1p/19q co-del and IDH wt groups, respectively. A correlation was not found between other genomic subgroups and MR imaging findings. Strict surgical removal is important to improve the prognosis of patients with grade III gliomas, especially for tumors with the IDH 1/2 mutation without the 1p/19q co-deletion. The MR finding of T1VL can be used to select candidates for more radical resection.
引用
收藏
页码:505 / 514
页数:9
相关论文
共 50 条
  • [31] Relevance of 1p and 19q for patients with who grade II/III gliomas
    Iwamoto, F. M.
    Nicolardi, L.
    Demopoulos, A.
    Barbashina, V.
    Ladanyi, M.
    DeAngelis, L. M.
    Hormigo, A.
    NEURO-ONCOLOGY, 2006, 8 (04) : 458 - 458
  • [32] Role of chromosomal 1p/19q co-deletion on the prognosis of oligodendrogliomas in Pakistan
    Tariq, M. U.
    Ahmed, Z.
    Moatter, T.
    ANNALS OF ONCOLOGY, 2017, 28 : 38 - 38
  • [33] PAV TREATMENT WITHOUT IMMEDIATE RADIOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIAL TUMOR WITH 1p/19q CO-DELETION
    Matsutani, Tomoo
    Hirono, Seiichiro
    Shinozaki, Natsuki
    Iwadate, Yasuo
    Saeki, Naokatsu
    NEURO-ONCOLOGY, 2014, 16
  • [34] Automated MRI based pipeline for segmentation and prediction of grade, IDH mutation and 1p19q co-deletion in glioma
    Decuyper, Milan
    Bonte, Stijn
    Deblaere, Karel
    Van Holen, Roel
    COMPUTERIZED MEDICAL IMAGING AND GRAPHICS, 2021, 88
  • [35] Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma
    Lin, Wanzun
    Qiu, Xianxin
    Sun, Pian
    Ye, Yuling
    Huang, Qingting
    Kong, Lin
    Lu, Jiade J.
    MOLECULAR THERAPY-ONCOLYTICS, 2021, 21 : 288 - 302
  • [36] Characterisation of isocitrate dehydrogenase gene mutant WHO grade 2 and 3 gliomas: MRI predictors of 1p/19q co-deletion and tumour grade
    Doig, D.
    Kachramanoglou, C.
    Dumba, M.
    Tona, F.
    Gontsarova, A.
    Limback, C.
    Jan, W.
    CLINICAL RADIOLOGY, 2021, 76 (10) : 785.e9 - 785.e16
  • [37] EXTENT AND PROGNOSTIC VALUE OF MGMT PROMOTOR METHYLATION DEPEND ON IDH MUTATION AND 1P19Q CO-DELETION IN GLIOMA WHO GRADE II
    Karschnia, Philipp
    Teske, Nico
    Siller, Sebastian
    Dorostkar, Mario M.
    Weller, Jonathan
    Herms, Jochen
    Baehring, Joachim M.
    von Baumgarten, Louisa
    Tonn, Joerg-Christian
    Thon, Niklas
    NEURO-ONCOLOGY, 2020, 22 : 170 - 170
  • [38] CLINICAL RESULTS OF THE EORTC RANDOMIZED PHASE II TAVAREC TRIAL ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB IN 1ST RECURRENCE OF GRADE II OR III GLIOMA WITHOUT 1p/19q CO-DELETION
    van den Bent, Martin
    Clement, Paul
    Vos, Filip
    Platten, Michael
    Mulholland, Paul
    Taphoorn, Martin
    Lewis, Joanne
    Gorlia, Thierry
    Golfinopoulos, Vassilis
    Idbaih, Ahmed
    Chinot, Olivier
    NEURO-ONCOLOGY, 2016, 18 : 3 - 3
  • [39] Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci
    Labreche, Karim
    Kinnersley, Ben
    Berzero, Giulia
    Di Stefano, Anna Luisa
    Rahimian, Amithys
    Detrait, Ines
    Marie, Yannick
    Grenier-Boley, Benjamin
    Hoang-Xuan, Khe
    Delattre, Jean-Yves
    Idbaih, Ahmed
    Houlston, Richard S.
    Sanson, Marc
    ACTA NEUROPATHOLOGICA, 2018, 135 (05) : 743 - 755
  • [40] Prognostic Role of EYA4 in Lower Grade Glioma with IDH1 Mutation and 1p19q Co-Deletion
    Zhu, Jin
    Hu, Li-Bo
    Zhao, Ya-Peng
    Zhang, Yu-Qi
    WORLD NEUROSURGERY, 2021, 149 : E1174 - E1179